Professor Richard Price
Contact information
Podcast interview
Curing Plasmodium vivax malaria
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Richard Price
Professor of Tropical Medicine
Vivax malaria
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with in malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria
- define the morbidity and mortality of vivax malaria
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN). Between 2010-2020 he established co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
CURRENT PROJECTS:
- Clinical trials and implementation studies of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Individual patient data metanalyses of antimalarial efficacy studies
Recent publications
A systematic review and individual patient data meta-analysis to determine the effect of primaquine dose on efficacy, tolerability and safety in uncomplicated Plasmodium vivax malaria in Latin America
Journal article
Nguyen K. et al, (2026), The Lancet Regional Health - Americas, 63, 101634 - 101634
Seven-day versus fourteen-day low-dose primaquine for Plasmodium vivax malaria in India: an open-label, non-inferiority, randomised, controlled trial
Journal article
Baharia RK. et al, (2026), The Lancet Regional Health - Southeast Asia, 53, 100849 - 100849
Community patient follow-up as a part of P. vivax case management in Cambodia: a mixed methods study
Journal article
Cassidy-Seyoum SA. et al, (2026), BMC Health Services Research
Genetic Evidence of Cross-Border Plasmodium vivax Spread in a Malaria Pre-elimination Region of South Asia
Conference paper
Rai A. et al, (2026), The Journal of Infectious Diseases, 234, e671 - e680
Temporal Changes in the Genetic Diversity and Relatedness of Plasmodium vivax Clinical Infections in Eastern Cambodia
Journal article
Eam R. et al, (2026), The Journal of Infectious Diseases
Identifiability and model misspecification for modelling recurrent infections using routine health care data
Journal article
Yan AWC. et al, (2026), American Journal of Epidemiology, 195, 2458 - 2468